
French Carthera closes €37.5m Series B financing round
A prominent (undisclosed) investor led the round alongside the European Innovation Council Fund (EICF) and existing investors including Panakès...

Oxford Biomedica expands agreement with Cabaletta Bio
Philadelphia-based clinical-stage biotech Cabaletta Bio focuses on developing and launching the first curative targeted cell therapies for patients...

NK cell therapy company NK:IO raises seed money
London-based UK New Cancer Therapeutics award winner (£1.6m) NK:IO Ltd has raised £1.2M bringing total equity financing to £3.2m. This,...

UK invests in biopharma manufacturers
The agency announced that seventeen new projects will receive funding for cutting edge medicine manufacturing, delivered by the Innovate UK...

Resistance blocker of immune checkpoint inhibitors gets patented
DT-9081, Domain Therapeutics’ selective EP4 receptor antagonist, preclinically synergised with PD1-checkpoint blockers and shrinked tumours by...

CEPI commits up to US$80m to University of Oxford to develop vaccines
The US$80m strategic partnership of CEPI, which was established in 2016 in the wake of the Ebola virus outbreak in west Africa, the University of...

Mystery solved: Mysthera Theapeutics launches with $3.5m
Mysthera Therapeutics AG was just founded in Basel, Switzerland by Forty51 Ventures with $3.5m seed capital. Pursuing a first-in-class...